One hundred and sixty-five women were treated during a total of 3,281 cycles with Neo-Lyndiol, a combined oral contraceptive containing 2·5 mg lynestrenol and 0·050 mg ethinyloestradiol per tablet. The tablets were taken for 32 days, with six tablet-free days.
No pregnancies were seen and the proportion of patients experiencing irregular bleeding and side-effects was very low and in fact their complaints decreased considerably as medication continued. There was a drop-out rate of only 5·5%, which is exceptionally low.
Neo-Lyndiol proved to be a reliable preparation, controlling the cycle well and causing few side-effects.
Get full access to this article
View all access options for this article.
References
1.
Aznar-RamosRGiner-VelázquezJLara-RicaldiRManautouJ Martínez (1969) Incidence of side-effects with contraceptive placebo. American Journal of Obstetrics and Gynecology105, 1144
BrehmH (1970) Wenig Pille—wenig Probleme?Ärztliche Praxis22, 3245
4.
CyranW (1971) Der differenzierte Einsatz der Ovulationshemmer (Indikationen und Kontraindikationen). Landarn47, 791
5.
DöringGK (1970a) Differcnzierter Einsatz von Ovulationshemmern. Deutsche medizinische Journal2, 5703
6.
DöringGK (1970b) Differenzierter Einsatz von Ovulationshemmern gezielter Wechsel der verschiedenen Präparate zur Vermeidung bzw. Abschwächung von Nebenwirkungen. Deutsche Ärzteblatt67, 1360
7.
DrillVA (1972) Oral contraceptives and thromboembolic disease. 1. Prospective and retrospective studies. Journal of the American Medical Association219, 583
8.
DrillVACalhounDW (1968) Oral contraceptives and thromboembolic disease. Journal of the American Medical Association206, 77
9.
DrillVACalhounDW (1972) Oral contraceptives and thromboembolic disease. II. Estrogen content of oral contraceptives. Journal of the American Medical Association219, 593
10.
Editorial (1962) Contraindications to oral contraception. British Medical Journal2, 315
11.
FrederiksenHRavenholtRT (1970) Thromboembolism, oral contraceptives, and cigarettes. Public Health Reports85, 197
12.
Fuertes-de la HabaACuretJ CPelegrinaIBangdiwalaI (1971) Thrombophlebitis among oral and nonoral contraceptive users. Obstetrics and Gynecology38, 259
13.
InmanWHWVesseyMPWesterholmBEngelundA (1970) Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. British Medical Journal2, 203
14.
KayC (1974) ‘Oral Contraceptives and Health. An interim report from the Oral Contraception Study of the Royal College of General Practitioners.’Pitman Medical: London
15.
KrauseJStammH (1970) Die Beurteilung hormonaler Konstitutionsvarianten im Hinblick auf die Vcrordning von oralen Kontrazeptiva. Verordning. Fortschritte der Geburtshilfe und Gynaekologie42, 57
16.
LauritzenCh (1971) Nebenwirkungen und differenzierte Anwendung von hormonalen Kontrazeptiva. Lecture at the 45th Meeting of the Essen Gynaecological Society, January 24th, 1971
17.
McIntyreNPhillipsMJVoigtJC (1962) Two cases of thromboembolic disease associated with oral contraceptives. British Medical Jonrnal2, 1029
18.
Medical Research Council, Subcommittee (1967) Risk of thromboembolic disease in women taking oral contraceptives. British Medical Journal2, 355
19.
PlothoB (1973) Nebenwirkungen und Schsädigungsmöglichkeiten der Ovulationshemmer. Wiener Medizinische Wochenschrift123, Supplt. 2, 3
20.
TenhaeffD (1971) Gezielter Einsatz von Ovulationshemmern. Ärztliche Praxis23, 3351
